Evopoint Biosciences, an innovative biopharmaceutical company in SIP, put its new small molecule drug manufacturing base into use recently.
Located in Suzhou Dushu Lake Sci-Edu Innovation District, the project covers a land area of about 30 mu (2 hectares), and its total floor area reaches nearly 44,000 square meters. The total investment was approximately RMB780 million.
Evopoint is a leading company in innovative small molecule drugs, with a strategic focus on precision oncology therapies and multidrug-resistant bacterial infections. The new facility is expected to accelerate the commercialization of the company’s R&D outcomes and provide strong support for its global expansion.
October 28, 2025
